Comparative Study of Intranasal, Subcutaneous and Intravenous Administration of Desamino-D-Arginine Vasopressin (DDAVP)

 

PDF Download Buy Article Permissions and Reprints

Summary

This study was performed to evaluate the influence of different routes of administration on the efficacy of DDAVP treatment. Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial. Factor XII and high molecular weight (HMW)-kininogen levels increased only slightly after DDAVP administration. The mean increase of factor VIII: C was 3.1 (i. v.), 2.3 (s. c.), and 1.3 (i.n.) - fold over baseline. Ristocetin cofactor (von Willebrand factor antigen) increased 3.1 (2.5), 2.0 (2.3) and 1.2 (1.2) - fold over baseline mean values after i.v., s.c. and i.n. DDAVP, respectively. The half-disappearance time of factor VIII and von Willebrand factor (vWF) after DDAVP ranged from five (factor VIII: C) to eight hours (vWF). The mean increase of fibrinolytic activity was more pronounced after i.v. DDAVP. The antidiuretic effect was moderate with no apparent differences between the routes of application. This study provides further evidence that both i.v. and s.c. DDAVP administration result in an appropriate and reliable stimulation of haemostasis. An additional advantage of s. c. administration is its suitability for home treatment.

• References

• 1 Edwards C RW, Kitau MJ, Chard T, Besser GM. Vasopressin analogue DDAVP in diabetes insipidus: Clinical and laboratory studies. Br Med J 1973; 3: 375-378
  CrossrefPubMedGoogle Scholar
• 2 Mannucci PM, Åberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93
  CrossrefPubMedGoogle Scholar
• 3 Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-deamino-8-D-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet 1977; 1: 869-872
  PubMedGoogle Scholar
• 4 Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. DDAVP in haemophilia. Lancet 1977; 2: 1171-1172
  PubMedGoogle Scholar
• 5 Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS. Deamino-8-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12
  CrossrefPubMedGoogle Scholar
• 6 Kobrinsky NL, Israels ED, Gerrard JM, Cheang MS, Watson CM, Bishop AJ, Schroeder ML. Shortening of the bleeding time by , 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984; 1: 1145-1148
  CrossrefPubMedGoogle Scholar
• 7 Jones P. Acquired immunodeficiency syndrome, hepatitis, and haemophilia. Br Med J 1983; 287: 1737
  CrossrefPubMedGoogle Scholar
• 8 Lancet Editorial. DDAVP in haemophilia and von Willebrand’s disease. Lancet 1983; II: 774-775
  PubMedGoogle Scholar
• 9 Warrier AI, Lusher JM. DDAVP: A useful alternative to blood components in moderate hemophilia A and von Willebrand’s disease. J Pediatr 1983; 102: 228-233
  CrossrefPubMedGoogle Scholar
• 10 Streit A, Furlan M, Beck EA. Desamino-8-Arginin Vasopressin-Nasentropfen zur Behandlung der milden Hamophilie A und des Morbus von Willebrand. Schweiz Med Wschr 1984; 114: 1389-1391
  PubMedGoogle Scholar
• 11 Köhler M, Hellstern P, Reiter B, von Blohn G, Wenzel E. The subcutaneous administration of the vasopressin analogue 1-desamino-8-D-arginine vasopressin in patients with von Willebrand’s disease and hemophilia. Klin Wschr 1984; 62: 543-548
  CrossrefPubMedGoogle Scholar
• 12 Peake IR, Bloom AL. Immunoradiometric assay of procoagulant factor VIII antigen in plasma and serum and its reduction in haemophilia. Preliminary studies on adult and foetal blood. Lancet 1978; I: 473-475
  PubMedGoogle Scholar
• 13 Nilsson IM, Mikaelsson M, Vilhardt H, Walter H. DDAVP factor VIII concentrate and its properties in vivo and in vitro. Thromb Res 1979; 15: 263-271
  CrossrefPubMedGoogle Scholar
• 14 Nenci GG, Berrettini M, DeCunto M, Agnelli G. Effect of DDAVP on plasma level of factor XII. Br J Haematol 1983; 54: 489-492
  CrossrefPubMedGoogle Scholar
• 15 Brommer EXP, Kluft C, Bertina RM, Alderkamp G HJ. Effect of DDAVP on plasma levels of factor VII and XII. Br J Haematol 1984; 57: 173-175
  CrossrefPubMedGoogle Scholar
• 16 Vicente V, Alberca I, Calles MI, Borrasca AL. Effect of DDAVP on contact phase of blood coagulation. Br J Haematol 1984; 56: 679-680
  CrossrefPubMedGoogle Scholar
• 17 Brommer E JP, Barrett-Bergshoeff MM, Allen RA, Schicht I, Bertina RM, Schalekamp M AD H. The use of Desmopressin acetate as a test of the fibrinolytic capacity of patients - analysis of responders and non-responders. Thromb Haemostas 1982; 48: 156-161
  PubMedGoogle Scholar
• 18 Mannucci PM, Rota L. Plasminogen activator response after DDAVP: A clinico-pharmacological study. Thromb Res 1980; 20: 69-76
  CrossrefPubMedGoogle Scholar
• 19 Blättler W, Jacky E, Müller M, Graf M. Der Einfluß von 1-Desamino-8-D-Arginin-Vasopressin (DDAVP) auf die Blutgerinnung bei Patien-ten mit Hämophilie A und gesunden Mannem. Schweiz Med Wschr 1979; 109: 1367-1368
  PubMedGoogle Scholar
• 20 Ludlam CA, Peake IR, Davies BL, Furlong RA, Bloom AL. Factor VIII and fibrinolytic response to deamino-8-D-arginine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand’s disease. Br J Haematol 1980; 45: 499-511
  CrossrefPubMedGoogle Scholar
• 21 Nilsson IM, Holmberg L, Åberg M, Vilhardt H. The release of plasminogen activator and factor VIII after injection of DDAVP in healthy volunteers and in patients with von Willebrand’s disease. Scand J Haematol 1980; 24: 351-359
  PubMedGoogle Scholar
• 22 Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIH/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol 1981; 47: 283-293
  CrossrefPubMedGoogle Scholar
• 23 Kobayashi I. Treatment of haemophilia A and von Willebrand’s disease patients with an intranasal dripping of DDAVP. Thromb Res 1979; 16: 775-779
  CrossrefPubMedGoogle Scholar
• 24 Göbel U, Untiedt H, von Voss H. Der Einfluß von DDAVP auf VIII :C und VIII: AG bei Normalpersonen nach intravenöser und nasaler Applikation. In: Minirin-DDAVP-Anwendung bei Blutern Sutor AH. (Ed.) F K Schattauer Verlag; Stuttgart - New York: 1980: 43-51
• 25 Vicente GarciaV, Alberca SilvaI, Borrasca AL. Response of factor VIH/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII). Thromb Haemostas 1982; 48: 91-93
  PubMedGoogle Scholar
• 26 Nilsson IM, Mikaelsson M, Vilhardt H. The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal patients. Scand J Haematol 1982; 29: 70-74
  PubMedGoogle Scholar
• 27 Barrowcliffe T. Comparisons of one-stage and two-stage assays of factor VIII :C. Scand J Haematol 1984; 33 (Suppl. 40) 39-54
  PubMedGoogle Scholar
• 28 Moffat EH, Giddings JC, Bloom AL. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Br J Haematol 1984; 57: 651-662
  CrossrefPubMedGoogle Scholar
• 29 Mikaelsson M, Nilsson IM, Vilhardt H, Wiechel B. Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of a vasopressin analogue. Transfusion 1982; 22: 229-233
  CrossrefPubMedGoogle Scholar
• 30 Kjellmann H. Calculations of factor VIII in vivo recovery and half-life. Scand J Haematol 1984; 33 (Suppl. 40) 165-174
  PubMedGoogle Scholar